Parabilis Medicines PBLS

Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Drug Manufacturers - General nearest Parabilis Medicines' size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
PBLSParabilis Medicines	$3B	n/m	n/a		n/m	n/m	n/m
NRIXNurix Therapeutics	$2.8B	11.0×	10.8×		3.9×	n/m	42.0%
OGNOrganon	$3.6B	17.9×	5.9×		0.6×	−2%	3.4%
LQDALiquidia	$3.8B	30.7×	53.6×		8.5×	n/m	30.7%
ARQTArcutis Biotherapeutics	$3.9B	142×	115×		8.5×	+76%	6.1%
PBHPrestige Consumer Healthcare	$2.3B	13.4×	15.3×		2.0×	−1%	15.6%
INDVIndivior Pharmaceuticals	$4.1B	12.4×	20.1×		3.1×	+13%	26.7%
HRMYHarmony Biosciences	$2.1B	11.7×	13.8×		2.2×	+24%	18.9%
ANIPANI Pharmaceuticals	$1.7B	15.4×	60.6×		1.7×	+31%	11.1%
PAHCPhibro Animal Health	$1.6B	15.9×	21.5×		1.0×	+17%	6.6%
KNSAKiniksa Pharmaceuticals International	$6B	79.1×	85.3×		7.1×	+59%	9.6%
Peer median	$3.2B	15.7×	20.8×		2.6×	+21%	13.3%

Each number over time

• Revenue

Its groups

• Drug Manufacturers - General
• Healthcare

Industry

Drug Manufacturers - General

Sector

Healthcare